Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.54
-0.40 (-1.74%)
At close: Aug 5, 2025, 4:00 PM
21.80
-0.74 (-3.28%)
After-hours: Aug 5, 2025, 5:50 PM EDT

Company Description

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.

It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.

The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.

The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.

Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences, Inc.
Pacira BioSciences logo
CountryUnited States
Founded2006
IPO DateFeb 3, 2011
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees790
CEOFrank Lee

Contact Details

Address:
5401 West Kennedy Boulevard, Suite 890
Tampa, Florida 33609
United States
Phone813 553 6680
Websitepacira.com

Stock Details

Ticker SymbolPCRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001396814
CUSIP Number695127100
ISIN NumberUS6951271005
Employer ID51-0619477
SIC Code2834

Key Executives

NamePosition
Frank D. LeeChief Executive Officer and Director
Shawn M. CrossChief Financial Officer
Lauren Bullaro RikerPrincipal Accounting Officer and Senior Vice President of Finance
Kristen Williams Esq., J.D.Chief Administrative Officer and Secretary
David M. StackAdvisor
Dr. Jonathan Slonin M.D.Chief Medical Officer
Susan MescoHead of Investor Relations
Anthony Molloy III, Esq.Chief Legal and Compliance Officer
Christopher C. YoungChief Manufacturing Officer
Krys Corbett Esq.Chief Business Officer

Latest SEC Filings

DateTypeTitle
Aug 5, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 5, 202510-QQuarterly Report
Aug 5, 20258-KCurrent Report
Jul 10, 20258-KCurrent Report
Jul 7, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 4, 2025144Filing
Jun 4, 2025144Filing
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report